‌about us

Is a proprietary stem cell that separates exosome from cord blood stem cells.We have the original technology.

This makes it possible to isolate and culture exosomes with enhanced 2-3 fold function, and mass-produce exosome with enhanced tissue regeneration and anti-inflammatory effects, not just exosome.

 

It possesses unrivaled clinical technology through 20 years of clinical trials in China, and is in consultation with China and Japan for cooperation treatment hospitals and exosome R&D and production facilities. <now. Prof. Chul-ki Min (Director of Korea Bloom Cell Joint Research Center) as a research institute in cooperation with the Department of Biotechnology at Ajou University is conducting joint research and development>

​

‌In addition, since there is a membraneless cell mass culture source technology and 3D stereoscopic culture technology, stable mass culture growth is possible in an environment similar to the human environment, which leads to a reduction in production cost and consequently lowers the market price, thereby reducing stem cells for rare intractable diseases. By providing treatment opportunities, it can be expected to contribute to public health and commercial success.

In addition, it has a data solution for conquering cancer by completing preclinical trials on gene therapy to prevent cancer cell proliferation by extracting cells from cancer patients' ascites. In addition, mass culture of stem cell exosomes With the completion of prototype development for the development of various wound and burn treatment products and beauty care products with the original technology, it can be expected to preoccupy the market.